108 completed, 37 terminated, 11 active not recruiting, 8 withdrawn. 91 Phase 1, 85 Phase 2, 13 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Recurrent Small Lymphocytic Lymphoma: new trials by email Literature Review of Recurrent Small Lymphocytic Lymphoma trials Research Report on Recurrent Small Lymphocytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-05-27 | 2026-10-06 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Acalabrutinib, Venetoclax, Biospecimen Collection - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2023-05-31 | 2026-05-18 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Daratumumab, Ibrutinib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2020-11-11 | 2025-12-30 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Obinutuzumab, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 168 | 2020-07-29 | 2026-09-10 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Duvelisib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 15 | 2020-05-13 | 2026-01-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial Laboratory Biomarker Analysis, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Pharmacological Study - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 9 | 2019-04-25 | 2023-06-15 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Ibrutinib, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Completed | Steven E. Coutre | 22 | 2017-09-26 | 2021-09-29 |
Showing 20 of 172. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (172) · Lymphoma, Follicular (125) · Lymphoma, B-Cell, Marginal Zone (123) · Lymphoma, Mantle-Cell (120) · Lymphoma, Large B-Cell, Diffuse (106) · Lymphoma, Non-Hodgkin (106) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (98) · Waldenstrom Macroglobulinemia (94) · Burkitt Lymphoma (90) · Lymphoma, Large-Cell, Immunoblastic (83) · Hodgkin Disease (75) · Lymphoma, T-Cell, Cutaneous (70) · Mycosis Fungoides (69) · Sezary Syndrome (69) · Lymphoma, Large-Cell, Anaplastic (60)
Chronic Disease (172) · Disease Attributes (172) · Hemic and Lymphatic Diseases (172) · Immune System Diseases (172) · Immunoproliferative Disorders (172) · Leukemia (172) · Leukemia, B-Cell (172) · Lymphatic Diseases (172) · Lymphoproliferative Disorders (172) · Neoplasms by Histologic Type (172) · Pathologic Processes (172) · Pathological Conditions, Signs and Symptoms (172) · Hematologic Diseases (171) · Leukemia, Lymphoid (171) · Neoplasms (171)
Rituximab (33) · fludarabine phosphate (33) · Cyclophosphamide (26) · Mycophenolic Acid (26) · Whole-Body Irradiation (26) · Peripheral Blood Stem Cell Transplantation (24) · Cyclosporine (19) · ibrutinib (15) · Lenalidomide (14) · Tacrolimus (12) · Bortezomib (10) · Etoposide (9) · Bendamustine Hydrochloride (8) · Biopsy (8) · Cyclosporins (8)
National Cancer Institute (NCI) (65) · Fred Hutchinson Cancer Center (36) · Mayo Clinic (11) · City of Hope Medical Center (9) · M.D. Anderson Cancer Center (9) · Case Comprehensive Cancer Center (7) · Roswell Park Cancer Institute (5) · Jonsson Comprehensive Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Robert Lowsky (2) · University of Washington (2) · Wake Forest University Health Sciences (2) · Academic and Community Cancer Research United (1) · Alexey Danilov, MD (1) · Amir Mortazavi (1)
United States (166) · Italy (9) · Germany (6) · Canada (3) · Denmark (2)
David Maloney (7) · Brenda Sandmaier (6) · Ajay Gopal (5) · John Byrd (4) · Mohamed Sorror (4) · Jennifer Woyach, MD (3) · Kristie Blum (3) · Paul Martin (3) · Anas Younes (2) · Brenda Cooper (2) · George Chen (2) · Jeffrey Jones (2) · Joseph M Tuscano (2) · Marco Mielcarek (2) · Mazyar Shadman (2)
PMID 32499241, PMID 34515338, PMID 17679729, PMID 19826119, PMID 19900571, PMID 20837940, PMID 21072184, PMID 21508413, PMID 21725056, PMID 22259028, PMID 22289993, PMID 22308288, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24990615, PMID 25085357, PMID 26182309, PMID 26213141, PMID 26764356, PMID 26853648, PMID 26943915, PMID 27111235, PMID 27118452, PMID 28270022, PMID 28314788, PMID 28424162, PMID 28714866, PMID 28817727, PMID 29038338, PMID 29292843, PMID 29572391, PMID 30454872, PMID 30530801, PMID 30562587, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31141631, PMID 31388792, PMID 31481800, PMID 31617432, PMID 31648294, PMID 32628342, PMID 32967009, PMID 33420905, PMID 33492438, PMID 34110383, PMID 34196037, PMID 34492703
P30CA015704 (23), U01CA076576 (14), P01CA018029 (8), P30CA016058 (8), P30CA015083 (7), P01CA078902 (5), U01CA062487 (5), U01CA062491 (5), U01CA062502 (5), U01CA062505 (5), U01CA099168 (5), P30CA033572 (4), N01CM17003 (3), N01CM62202 (3), P50CA097274 (3)